24688-36-6

Basic information

• Product Name: 2-methyl-6-nitro-4(3H)-Quinazolinone
• Synonyms: 2-methyl-6-nitro-4(3H)-Quinazolinone;2-METHYL-6-NITRO-3H-QUINAZOLIN-4-ONE
• CAS NO: 24688-36-6
• Molecular Formula: C₉H₇N₃O₃
• Molecular Weight: 205.17018
• Mol File: 24688-36-6.mol
• Article Data: 24

Chemical Properties

• Melting Point: 299 °C
• Boiling Point: 401.4°Cat760mmHg
• Flash Point: 196.6°C
• Appearance: /
• Density: 1.55g/cm³
• Vapor Pressure: 1.18E-06mmHg at 25°C
• Refractive Index: 1.708
• PKA: -0.10±0.20(Predicted)
• CAS DataBase Reference: 2-methyl-6-nitro-4(3H)-Quinazolinone(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methyl-6-nitro-4(3H)-Quinazolinone(24688-36-6)
• EPA Substance Registry System: 2-methyl-6-nitro-4(3H)-Quinazolinone(24688-36-6)

Safety Data

• Hazardous Substances Data: 24688-36-6(Hazardous Substances Data)

Usage

General Description

2-methyl-6-nitro-4(3H)-Quinazolinone is a chemical compound with the molecular formula C9H7N3O3. It is a yellow crystalline solid with a molecular weight of 193.17 g/mol. 2-methyl-6-nitro-4(3H)-Quinazolinone is used in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceuticals, including antihistamines and anti-inflammatory drugs. It is also used as a precursor for the synthesis of dyes and pigments. Additionally, 2-methyl-6-nitro-4(3H)-Quinazolinone has been studied for its potential anti-cancer properties, making it an important target for medicinal chemistry research.

InChI:InChI=1/C9H7N3O3/c1-5-10-8-3-2-6(12(14)15)4-7(8)9(13)11-5/h2-4H,1H3,(H,10,11,13)

Upstream product

• 1769-24-0 2-methyl-4-quinazolone 
• 703-63-9 2,4-dimethylquinazoline 
• 73894-38-9 N-(2-cyano-4-nitrophenyl)acetamide 
• 16313-65-8 2-amino-5-nitrobenzamide 
• 123-54-6 acetylacetone 
• 7664-93-9 sulfuric acid 
• 7697-37-2 nitric acid 
• 525-76-8 2-methyl-4-oxo-3,1-benzoxazine 
• 89-52-1 o-acetylamino-benzoic acid 
• 17420-30-3 5-nitroanthranilonitrile 
• 10073-89-9 2-methyl-6-nitro-4H-benzo[d][1,3]oxazin-4-one 
• 78-39-7 Triethyl orthoacetate 
• 616-79-5 2-amino-5-nitro-benzoic acid 
• 124-42-5 acetamidine hydrochloride 

Downstream Products

• 73673-70-8 2-(4-methyl-styryl)-6-nitro-3H-quinazolin-4-one 
• 17329-24-7 6-amino-3,4-dihydro-2-methyl-4-oxoquinazoline 
• 74151-22-7 4-chloro-6-nitro-2-methylquinazoline 
• 128031-43-6 6-Amino-2-{(E)-2-[4-((E)-styryl)-phenyl]-vinyl}-3H-quinazolin-4-one 
• 128031-42-5 6-Nitro-2-{(E)-2-[4-((E)-styryl)-phenyl]-vinyl}-3H-quinazolin-4-one 
• 163732-38-5 6-Amino-2-((E)-2-{4-[(E)-2-(4-chloro-phenyl)-vinyl]-phenyl}-vinyl)-3H-quinazolin-4-one 
• 163732-37-4 2-((E)-2-{4-[(E)-2-(4-Chloro-phenyl)-vinyl]-phenyl}-vinyl)-6-nitro-3H-quinazolin-4-one 
• 179910-70-4 6-Amino-2-((E)-2-{4-[(E)-2-(4-dimethylamino-phenyl)-vinyl]-phenyl}-vinyl)-3H-quinazolin-4-one 
• 179910-66-8 2-((E)-2-{4-[(E)-2-(4-Dimethylamino-phenyl)-vinyl]-phenyl}-vinyl)-6-nitro-3H-quinazolin-4-one 

Relevant articles and documents

Isoxazole formamido-4 (3H)-quinazolinone derivative as well as synthesis method and application thereof

The invention relates to a 6-(isoxazolyl-3-formamido)-4 (3H)-quinazolinone derivative as well as a synthesis method and application thereof, belongs to the technical field of medicines, and relates to a general formula (I) in which R1, R2 and R3 are different substituent groups. The invention discloses structures and synthesis methods of the compounds, inhibitory activity of acetylcholin esterase and inhibitory activity of protein tyrosine phosphatase, and the compounds can be further developed into drugs for treating Alzheimer's disease.

Small molecules inhibit STAT3 activation, autophagy, and cancer cell anchorage-independent growth

Triple-negative breast cancers (TNBCs) lack the signature targets of other breast tumors, such as HER2, estrogen receptor, and progesterone receptor. These aggressive basal-like tumors are driven by a complex array of signaling pathways that are activated by multiple driver mutations. Here we report the discovery of 6 (KIN-281), a small molecule that inhibits multiple kinases including maternal leucine zipper kinase (MELK) and the non-receptor tyrosine kinase bone marrow X-linked (BMX) with single-digit micromolar IC50s. Several derivatives of 6 were synthesized to gain insight into the binding mode of the compound to the ATP binding pocket. Compound 6 was tested for its effect on anchorage-dependent and independent growth of MDA-MB-231 and MDA-MB-468 breast cancer cells. The effect of 6 on BMX prompted us to evaluate its effect on STAT3 phosphorylation and DNA binding. The compound's inhibition of cell growth led to measurements of survivin, Bcl-XL, p21WAF1/CIP1, and cyclin A2 levels. Finally, LC3B-II levels were quantified following treatment of cells with 6 to determine whether the compound affected autophagy, a process that is known to be activated by STAT3. Compound 6 provides a starting point for the development of small molecules with polypharmacology that can suppress TNBC growth and metastasis.

6-amino-4(3H)-quinazolinone derivatives and their synthesis method and use

The invention discloses 6-amino-4(3H)-quinazolinone derivatives and their synthesis method and use and belongs to the technical field of drug synthesis. The invention also relates to a use of the 6-amino-4(3H)-quinazolinone derivatives with a general formula (I) and its synthesis method in medical science, wherein in the general formula (I), X represents (CH2)n-1, n=1 to 10 and R1, R2 and R3 represent different substituents. The invention discloses the compound structures and their synthesis method and external acetylcholinesterase inhibition activity. The 6-amino-4(3H)-quinazolinone derivatives can be further studied and developed to form novel drugs for treating Alzheimer disease.